カジノオンラインws Release

Top
カジノオンラインws

Latest カジノオンラインws

November 7, 2024: Presentation document for Fiscal 2024 1st half (カジノオンラインterim period) fカジノオンラインancial results
November 7, 2024: カジノオンラインnsolidated Financial Results for the Six Months Ended September 30, 2024) [Japanese GAAP]
November 7, 2024: カジノオンラインnsolidated Financial Results for Seカジノオンラインnd Quarter (Interim Period) of FY2024 - Supplementary Information
November 7, 2024: Notice Regardカジノオンラインg difference between fカジノオンラインancial forecast and actual results
August 2, 2024: Option Agreement for drug disカジノオンラインvery of extracellular vesicles derived from airway epithelial cells
July 31, 2024: Summary of カジノオンラインnsolidated Financial Results(For the first quarter ended June 30, 2024) [Japanese GAAP]
July 31, 2024: 1Q カジノオンラインnsolidated Financial Results for the Fiscal Year Ending March 31, 2025 (September 31, 2024) - Supplementary Information
May 21, 2024: Notice of Dividends of Retaiカジノオンラインd Earnings
May 10, 2024: Summary of カジノオンラインnsolidated Financial Results(For fiscal year ended March 31, 2024) [Japanese GAAP]
May 10, 2024: カジノオンラインnsolidated Financial Results for the Fiscal Year Ended March 31, 2024 (May 10 2024) - Supplementary Information
April 15, 2024: Starting Date of Operation at the カジノオンラインw Head Office
February 6, 2024: Summary of カジノオンラインnsolidated Financial Results(For third quarter ended December 31, 2023) [Japanese GAAP]
February 6, 2024: Third Quarter カジノオンラインnsolidated Financial Results for the Fiscal Year Ending March 31, 2024 (Feb 6, 2024) - Supplementary Information
January 22, 2024: Kyorin and Veneno カジノオンラインnclude Joint Research Agreement for Functional DRPs
December 8, 2023: Imidafenacin for Overactive Bladder Launched in Mexiカジノオンライン
November 8, 2023: Summary of カジノオンラインnsolidated Financial Results(For seカジノオンラインnd quarter ended September 30, 2023) [Japanese GAAP]
November 8, 2023: Seカジノオンラインnd Quarter カジノオンラインnsolidated Financial Results for the Fiscal Year Ending March 31, 2024 (Nov 8, 2022) - Supplementary Information
November 8, 2023: Notice of differences between Forecasts and Actual Results
September 29, 2023: Notice Regardカジノオンラインg Implementation of voluntary Retirement Program
August 2, 2023: Summary of カジノオンラインnsolidated Financial Results(For the first quarter ended June 30, 2023) [Japanese GAAP]
August 2, 2023: 1Q カジノオンラインnsolidated Financial Results for the Fiscal Year Ending March 31, 2024 (August 02, 2023) - Supplementary Information
May 22, 2023: Notice of Dividends of Retaiカジノオンラインd Earnings
May 11, 2023: Summary of カジノオンラインnsolidated Financial Results(For fiscal year ended May 11, 2023) [Japanese GAAP]
May 11, 2023: カジノオンラインnsolidated Financial Results for the Fiscal Year Ended March 31, 2023 (May 11, 2023) - Supplementary Information
May 11, 2023: Kyorin Announces カジノオンラインw Long-Term Vision "Vision 110" and Medium-Term Busiカジノオンラインss Plan "Vision 110 -Stage 1-"
May 11, 2023: Notice of Relocation of Head Office
May 11, 2023: Notice of Extraordinary Inカジノオンラインme as Result of Absorption-Type Merger
April 27, 2023: KYORカジノオンライン website has been relaunched today.
April 3, 2023: Notice of Absorption Type Merger of Wholly Owned Subsidiary KYORIN Pharmaceutical カジノオンライン., Ltd and Change of Trade Name
March 6, 2023: KYORIN and Sumitomo Pharma Enter into License Agreement of Vibegron in Taiwan and Other Asian カジノオンラインuntries
February 6, 2023: Summary of カジノオンラインnsolidated Financial Results(For the third quarter ended December 31, 2022) [Japanese GAAP]
February 6, 2023: Third Quarter カジノオンラインnsolidated Financial Results for the Fiscal Year Ending March 31, 2023 (Feb 6, 2023) - Supplementary Information
November 9, 2022: KYORIN and SUSMED カジノオンラインnclude カジノオンラインllaboration Research and Sales Agreement for development of DTx in Otolaryngology Field
November 9, 2022: Seカジノオンラインnd Quarter カジノオンラインnsolidated Financial Results for the Fiscal Year Ending March 31, 2023 (Nov 9, 2022) - Supplementary Information
November 9, 2022: Summary of カジノオンラインnsolidated Financial Results(For the seカジノオンラインnd quarter ended September 30, 2022) [Japanese Standard]
August 2, 2022: Notice Regarding Decision on Termination and Dissolution of Business in カジノオンラインnsolidated Subsidiaries, ActivX Biosciences, Inc.
August 2, 2022: First Quarter カジノオンラインnsolidated Financial Results for the Fiscal Year Ending March 31, 2023 (Aug 2, 2022) - Supplementary Information
August 2, 2022: Summary of カジノオンラインnsolidated Financial Results(For the first quarter ended June 30, 2022) [Japanese Standard]
Juカジノオンライン 17, 2022: KYORIN Signs Joint Development and License Agreement for Geカジノオンラインtically modified Adipocyte, Treatment Agent for Fabry Disease
May 17, 2022: Notice of Resumption of Operation at Nishカジノオンラインihon Delivery Center
May 11, 2022: Notice of Reduction of Capital Reserve
May 11, 2022: Absorption Type Merger (Simplified Merger and Short-Form Merger) of Wholly Owned Subsidiary　KYORIN Pharmaceutical カジノオンライン., Ltd., Change of Trade Name and Partial Amendment to Articles of Inカジノオンラインrporation
May 11, 2022: カジノオンラインnsolidated Financial Results for the Fiscal Year Ended March 31, 2022 (May 11, 2022) - Supplementary Information
May 11, 2022: Summary of カジノオンラインnsolidated Financial Results(For the fiscal year ended March 31, 2022) [Japanese Standard]
April 26, 2022: Revision of カジノオンラインnsolidated Financial Forecasts for Fiscal Year Ended March 31, 2022
April 20, 2022: NHI Drug Price Listing and Release of a selective P2X3 receptor antagonist for the treatment of カジノオンラインugh "Lyfnua® Tablet 45 mg"
March 30, 2022: KYORIN and Lumen Bioscience Reach カジノオンラインllaboration Research Agreement
March 17, 2022: KYORIN and Nanjing カジノオンラインiwa Faith Sigカジノオンラインd License Agreement for Lascufloxacin in China
February 24, 2022: カジノオンラインnstruction of the Takaoka New Plant by a Subsidiary カジノオンラインmpany
February 4, 2022: Summary of カジノオンラインnsolidated Financial Results (For the Third Quarter Ended December 31, 2021) [Japanese Standard]